Speaker Profile

M.D., Ph.D., VP of Translational Medicine, BioFluidica

With over twenty years of experience in oncology, liquid biopsy, and molecular diagnostics, Dr. Wang will bring his expertise in clinical research, product development, and management to BioFluidica in 2022. As Vice President of Translational Medicine at BioFluidica, he drives and manages disease initiatives and clinical applications. Before joining BioFluidica, Dr. Wang served as the Vice President of Informatics at Mindera Health, Senior Director of Translational Research at Epic Sciences, and Director of Bioinformatics at AltheaDx, where he led the development of multiple clinical tests, genomics analysis pipelines, and machine learning algorithms. Mr. Wang has over 60 peerreviewed publications in journals, including sciences, PNAS, Blood and Cancer Research, etc. He earned an M.D. and Ph.D. from Jilin University and a certificate in business management.


Clinical Dx Showcase:

BioFluidica innovates technology and processes to overcome the technical challenges that hinder the clinical application of liquid biopsy. BioFluidica created LiquidScan™ as an automated system for isolating and enriching circulating rare cells and exosomes from liquid biopsy samples and developed clinical molecular tests.

Accelerating Development of Liquid Biopsy Clinical Applications
LiquidScan, a rare cell and exosome enrichment system, has been adopted for various clinical applications.

 Session Abstract – PMWC 2023 Silicon Valley

Showcase Track S2 - January 25 9.00 A.M.-1.15 P.M.,Showcase Track S2 - January 26 9.00 A.M.-4.45 P.M.,Showcase Track S2 - January 27 9.00 A.M.-2.15 P.M.

The PMWC 2023 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

  • Clinical Dx/Oncology (including Liquid Biopsy)
  • Clinical Dx/Cardio Vascular
  • Clinical Dx/Nerodegenerative